Spots Global Cancer Trial Database for Efficacy Study of CYT997 in Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy Study of CYT997 in Multiple Myeloma
Official Title: A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma
Study ID: NCT00664378
Conditions
Interventions
Study Description
Brief Summary: This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Alfred Hospital, Melbourne, Victoria, Australia
Contact Details
Name: Andrew Spencer, Assoc Prof.
Affiliation: Myeloma Research Group, The Alfred Hospital, Melbourne
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
